MaRS tenant draws kudos for migraine drug

Windhover Information Inc. — one of the world’s leaders in health-care strategy, industry trends and medical start-up analysis — has selected a migraine compound in development by a MaRS tenant as one of its Top 10 most promising neuroscience projects available for strategic partnering.

NeurAxon Inc., a tenant at MaRS since 2005, develops next-generation pain therapeutics. Its novel drug for treatment of migraine with aura, known as NXN-188, was tapped as one of the Top 10 most promising projects out of hundreds evaluated.

“We are extremely proud that NXN-188 has been selected as one of the Top 10 neuroscience projects available for partnering, further recognizing nNOS (neuronal nitric oxide synthase) inhibition as a fundamentally new mechanism to address very significant unmet needs and markets for a broad range of pain indications,” said NeurAxon CEO Dr. Lawrence Bloch.

As a selected company, NeurAxon has been invited to present data on NXN-188 at Windhover’s Therapeutic Area Parnerships conference taking place November 3-5, 2008, in Philadelphia.

Read NeurAxon’s news release here: “NeurAxon’s NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover”.